Statins considered safe for children with hereditary high cholesterol levels

Statins considered safe for children with hereditary high cholesterol levels

January 18 2018 A new study has found no statin-related safety issues for statins being used to...

Drug Safety Update includes eluxadoline, fingolimod

Drug Safety Update includes eluxadoline, fingolimod

December 19 2017 The MHRA’s latest Drug Safety Update includes information about two black...

Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

December 13 2017 Women using hormonal contraceptives are exposed to a 20% increased risk of...

MHRA issues new batch of Drug Safety Update notices

MHRA issues new batch of Drug Safety Update notices

November 28 2017 The medicines regulator has issued four Drug Safety Updates relating to...

Vitamin D intake guidance for pregnant mums and babies updated in Scotland

Vitamin D intake guidance for pregnant mums and babies updated in Scotland

November 27 2017 NHS Scotland has updated its recommendations around vitamin D intake for new...

  • Statins considered safe for children with hereditary high cholesterol levels

    Statins considered safe for children with hereditary high cholesterol levels

    Thursday, 18 January 2018 11:07
  • Drug Safety Update includes eluxadoline, fingolimod

    Drug Safety Update includes eluxadoline, fingolimod

    Tuesday, 19 December 2017 10:16
  • Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

    Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

    Wednesday, 13 December 2017 12:33
  • MHRA issues new batch of Drug Safety Update notices

    MHRA issues new batch of Drug Safety Update notices

    Tuesday, 28 November 2017 09:52
  • Vitamin D intake guidance for pregnant mums and babies updated in Scotland

    Vitamin D intake guidance for pregnant mums and babies updated in Scotland

    Monday, 27 November 2017 14:50

a vaccination syringes image cbOctober 23 2017

A shortage of the pneumococcal polysaccharide vaccine has promoted a Chief Medical Officer letter to GPs recommending how stocks can best be managed.

The current shortage of the PPV23 vaccine is anticipated to continue for some time. “There is only one licensed vaccine available and although the company are expecting more stock deliveries during October, the volume anticipated is unlikely to be sufficient to vaccinate the whole 65 year old cohort this winter,” says the letter from the Welsh CMO and NHS Wales Medical Director Dr Frank Atherton.

He summarises the three main recommendations in the letter as:

  • practices should plan to deliver the bulk vaccine programme across the year;
  • for patients at high risk, it is important to ensure that other preventive measures, including influenza vaccination, are implemented;
  • the records of such patients should be flagged so that they can be called for vaccine once the stock situation improves.

A table sets out priority groups for PPV23 vaccination, ranking them into high, moderate and low priority. The letter notes that “there is no shortage of the PCV13 vaccine used in infants and toddlers but this vaccine is not suitable for protection of older people.”

Links:
GP One coverage              
CMO letter CEM/CMO/2017/4b

Clinical News

January 22 2018 An updated respiratory health plan for Wales has been published, taking forward the national strategy for the next three years.